Header Logo

Connection

MICHAEL TAYLOR to Brain Neoplasms

Back to Details
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Brain Neoplasms.
MICHAEL TAYLOR
Connection Strength
9.822
Brain Neoplasms
  1. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.332
  2. Postoperative isolated lower extremity supplementary motor area syndrome: case report and review of the literature. Childs Nerv Syst. 2020 01; 36(1):189-195.
    View in: PubMed
    Score: 0.321
  3. Bioinformatic Strategies for the Genomic and Epigenomic Characterization of Brain Tumors. Methods Mol Biol. 2019; 1869:37-56.
    View in: PubMed
    Score: 0.303
  4. CAR T cells for childhood diffuse midline gliomas. Nat Med. 2018 05; 24(5):534-535.
    View in: PubMed
    Score: 0.289
  5. Review of molecular classification and treatment implications of pediatric brain tumors. Curr Opin Pediatr. 2018 02; 30(1):3-9.
    View in: PubMed
    Score: 0.284
  6. Fall of the Optical Wall: Freedom from the Tyranny of the Microscope Improves Glioma Risk Stratification. Cancer Cell. 2016 Feb 08; 29(2):137-8.
    View in: PubMed
    Score: 0.248
  7. The Amazing and Deadly Glioma Race. Cancer Cell. 2015 Sep 14; 28(3):275-7.
    View in: PubMed
    Score: 0.241
  8. Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl). 2015 Oct; 93(10):1075-84.
    View in: PubMed
    Score: 0.241
  9. Emerging insights into the ependymoma epigenome. Brain Pathol. 2013 Mar; 23(2):206-9.
    View in: PubMed
    Score: 0.202
  10. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012 May 08; 8(6):340-51.
    View in: PubMed
    Score: 0.191
  11. The epigenetics of brain tumors. Methods Mol Biol. 2012; 863:139-53.
    View in: PubMed
    Score: 0.186
  12. Molecular genetics of ependymoma. Chin J Cancer. 2011 Oct; 30(10):669-81.
    View in: PubMed
    Score: 0.183
  13. Intracerebral malignant peripheral nerve sheath tumor in a child with neurofibromatosis Type 1 and middle cerebral artery aneurysm treated with endovascular coil embolization. J Neurosurg Pediatr. 2011 Oct; 8(4):346-52.
    View in: PubMed
    Score: 0.183
  14. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol. 2010 Nov; 120(5):553-66.
    View in: PubMed
    Score: 0.171
  15. The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep. 2010 May; 10(3):215-23.
    View in: PubMed
    Score: 0.166
  16. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus. 2010 Jan; 28(1):E6.
    View in: PubMed
    Score: 0.162
  17. The genetic and epigenetic basis of ependymoma. Childs Nerv Syst. 2009 Oct; 25(10):1195-201.
    View in: PubMed
    Score: 0.156
  18. Co-occurrence of congenital anomalies and childhood brain tumors in 22 million live births. Neuro Oncol. 2025 Sep 08; 27(7):1910-1922.
    View in: PubMed
    Score: 0.120
  19. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nat Commun. 2025 Mar 26; 16(1):2974.
    View in: PubMed
    Score: 0.117
  20. The T cell receptor landscape of childhood brain tumors. Sci Transl Med. 2025 Mar 19; 17(790):eadp0675.
    View in: PubMed
    Score: 0.116
  21. FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma. Cancer Res. 2025 Jan 15; 85(2):231-250.
    View in: PubMed
    Score: 0.115
  22. Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding. Cancer Cell. 2025 Jan 13; 43(1):122-143.e8.
    View in: PubMed
    Score: 0.115
  23. Protocol for preclinical evaluation of locoregionally delivered CAR T?cells in patient-derived xenograft models of brain tumors. STAR Protoc. 2024 06 21; 5(2):103078.
    View in: PubMed
    Score: 0.110
  24. Complications following resection of primary and recurrent pediatric posterior fossa ependymoma. J Neurosurg Pediatr. 2024 04 01; 33(4):367-373.
    View in: PubMed
    Score: 0.107
  25. Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. Nat Cancer. 2024 Jan; 5(1):147-166.
    View in: PubMed
    Score: 0.107
  26. Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer Discov. 2023 04 03; 13(4):974-1001.
    View in: PubMed
    Score: 0.102
  27. Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular?era. J Neurooncol. 2023 Feb; 161(3):573-582.
    View in: PubMed
    Score: 0.101
  28. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma. Cancer Res. 2022 12 16; 82(24):4586-4603.
    View in: PubMed
    Score: 0.100
  29. Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data. BMC Cancer. 2022 Dec 12; 22(1):1297.
    View in: PubMed
    Score: 0.099
  30. Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature. 2022 12; 612(7941):787-794.
    View in: PubMed
    Score: 0.099
  31. Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. J Clin Oncol. 2023 02 01; 41(4):766-777.
    View in: PubMed
    Score: 0.098
  32. A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science. 2022 10 07; 378(6615):68-78.
    View in: PubMed
    Score: 0.098
  33. A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Mol Med. 2022 03 07; 14(3):e14552.
    View in: PubMed
    Score: 0.094
  34. Spatial concordance of DNA methylation classification in diffuse glioma. Neuro Oncol. 2021 12 01; 23(12):2054-2065.
    View in: PubMed
    Score: 0.093
  35. Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets. Neuro Oncol. 2021 05 05; 23(5):718-731.
    View in: PubMed
    Score: 0.089
  36. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discov. 2021 06; 11(6):1454-1467.
    View in: PubMed
    Score: 0.088
  37. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
    View in: PubMed
    Score: 0.086
  38. Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. Acta Neuropathol Commun. 2020 10 28; 8(1):173.
    View in: PubMed
    Score: 0.086
  39. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020 10 14; 22(10):1474-1483.
    View in: PubMed
    Score: 0.086
  40. DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. Dev Cell. 2020 08 24; 54(4):455-470.e5.
    View in: PubMed
    Score: 0.084
  41. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 04 13; 37(4):569-583.e5.
    View in: PubMed
    Score: 0.083
  42. Introduction. Pediatric brain tumor. Neurosurg Focus. 2020 01 01; 48(1):E1.
    View in: PubMed
    Score: 0.081
  43. Stalled developmental programs at the root of pediatric brain tumors. Nat Genet. 2019 12; 51(12):1702-1713.
    View in: PubMed
    Score: 0.081
  44. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun. 2019 09 25; 10(1):4343.
    View in: PubMed
    Score: 0.080
  45. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019 08; 16(8):509-520.
    View in: PubMed
    Score: 0.079
  46. Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. Nat Rev Clin Oncol. 2019 08; 16(8):522-523.
    View in: PubMed
    Score: 0.079
  47. ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. Cancer Res. 2019 08 15; 79(16):4057-4071.
    View in: PubMed
    Score: 0.078
  48. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 2019 07 08; 36(1):51-67.e7.
    View in: PubMed
    Score: 0.078
  49. High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res. 2019 08; 29(8):1211-1222.
    View in: PubMed
    Score: 0.078
  50. Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell. 2019 09 05; 25(3):433-446.e7.
    View in: PubMed
    Score: 0.078
  51. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019 05 01; 79(9):2111-2123.
    View in: PubMed
    Score: 0.077
  52. Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. Cancer Res. 2019 03 01; 79(5):905-917.
    View in: PubMed
    Score: 0.076
  53. Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma. Mol Oncol. 2018 04; 12(4):495-513.
    View in: PubMed
    Score: 0.071
  54. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. Acta Neuropathol. 2018 04; 135(4):617-634.
    View in: PubMed
    Score: 0.071
  55. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017 Sep 01; 35(25):2934-2941.
    View in: PubMed
    Score: 0.068
  56. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Childs Nerv Syst. 2017 Jul; 33(7):1047-1051.
    View in: PubMed
    Score: 0.068
  57. Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes Cancer. 2017 08; 56(8):639-650.
    View in: PubMed
    Score: 0.068
  58. Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017 03 15; 9(381).
    View in: PubMed
    Score: 0.067
  59. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017 01; 133(1):5-12.
    View in: PubMed
    Score: 0.065
  60. PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. Cancer Res. 2016 08 15; 76(16):4708-19.
    View in: PubMed
    Score: 0.063
  61. Evasion of Cell Senescence Leads to Medulloblastoma Progression. Cell Rep. 2016 Mar 29; 14(12):2925-37.
    View in: PubMed
    Score: 0.062
  62. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016 04; 17(4):484-495.
    View in: PubMed
    Score: 0.062
  63. An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 2016 Jan; 19(1):10-9.
    View in: PubMed
    Score: 0.061
  64. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729.
    View in: PubMed
    Score: 0.061
  65. Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. J Neurosurg Pediatr. 2016 Mar; 17(3):298-302.
    View in: PubMed
    Score: 0.061
  66. Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes. Oncotarget. 2015 Nov 17; 6(36):38881-900.
    View in: PubMed
    Score: 0.061
  67. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015 Sep; 18(9):1236-46.
    View in: PubMed
    Score: 0.060
  68. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
    View in: PubMed
    Score: 0.058
  69. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015 Mar; 47(3):257-62.
    View in: PubMed
    Score: 0.058
  70. Sleeping Beauty mouse models identify candidate genes involved in gliomagenesis. PLoS One. 2014; 9(11):e113489.
    View in: PubMed
    Score: 0.057
  71. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014 Nov 15; 20(22):5630-40.
    View in: PubMed
    Score: 0.057
  72. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol. 2014 Dec; 128(6):853-62.
    View in: PubMed
    Score: 0.057
  73. The G protein a subunit Gas is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014 Sep; 20(9):1035-42.
    View in: PubMed
    Score: 0.056
  74. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathol. 2014 Dec; 128(6):863-77.
    View in: PubMed
    Score: 0.056
  75. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303.
    View in: PubMed
    Score: 0.055
  76. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014 Jul; 128(1):137-49.
    View in: PubMed
    Score: 0.055
  77. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014 Aug; 128(2):279-89.
    View in: PubMed
    Score: 0.053
  78. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan; 46(1):39-44.
    View in: PubMed
    Score: 0.053
  79. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29.
    View in: PubMed
    Score: 0.053
  80. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res. 2013 Oct 15; 73(20):6310-22.
    View in: PubMed
    Score: 0.053
  81. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Res. 2013 Nov 15; 73(22):6734-44.
    View in: PubMed
    Score: 0.052
  82. Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. Cancer Res. 2013 Sep 01; 73(17):5381-90.
    View in: PubMed
    Score: 0.052
  83. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32.
    View in: PubMed
    Score: 0.052
  84. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013 May; 14(6):534-42.
    View in: PubMed
    Score: 0.051
  85. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16; 22(4):425-37.
    View in: PubMed
    Score: 0.049
  86. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol. 2012 Nov; 22(6):848-60.
    View in: PubMed
    Score: 0.048
  87. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012 May 15; 21(5):601-613.
    View in: PubMed
    Score: 0.048
  88. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012 Jan 20; 148(1-2):59-71.
    View in: PubMed
    Score: 0.047
  89. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1541-8.
    View in: PubMed
    Score: 0.047
  90. Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res. 2012 Feb 01; 72(3):636-44.
    View in: PubMed
    Score: 0.046
  91. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res. 2012 Jan 01; 72(1):122-32.
    View in: PubMed
    Score: 0.046
  92. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011 Oct 10; 29(29):3852-61.
    View in: PubMed
    Score: 0.046
  93. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011 Aug 16; 20(2):143-57.
    View in: PubMed
    Score: 0.045
  94. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 01; 29(19):2717-23.
    View in: PubMed
    Score: 0.045
  95. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010 Jun 15; 16(12):3240-52.
    View in: PubMed
    Score: 0.041
  96. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 08; 16(6):533-46.
    View in: PubMed
    Score: 0.040
  97. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 2008 Dec 01; 68(23):9945-53.
    View in: PubMed
    Score: 0.038
  98. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatr. 2008 Apr; 1(4):305-13.
    View in: PubMed
    Score: 0.036
  99. Protocol for the derivation of primary cancer stem cell lines from human ependymal tumors. STAR Protoc. 2024 09 20; 5(3):103260.
    View in: PubMed
    Score: 0.028
  100. TULIPs decorate the three-dimensional genome of PFA ependymoma. Cell. 2024 Sep 05; 187(18):4926-4945.e22.
    View in: PubMed
    Score: 0.028
  101. Imaging of murine brain tumors using a 1.5 Tesla clinical MRI system. Can J Neurol Sci. 2003 Nov; 30(4):326-32.
    View in: PubMed
    Score: 0.026
  102. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. PLoS One. 2020; 15(12):e0243272.
    View in: PubMed
    Score: 0.022
  103. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. 2020 06 11; 181(6):1329-1345.e24.
    View in: PubMed
    Score: 0.021
  104. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. 2019 09 16; 36(3):302-318.e7.
    View in: PubMed
    Score: 0.020
  105. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. 2016 Mar 14; 29(3):379-393.
    View in: PubMed
    Score: 0.016
  106. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget. 2015 Aug 28; 6(25):21718-29.
    View in: PubMed
    Score: 0.015
  107. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013 May 23; 153(5):1064-79.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.